Trial Profile
A comparison of Infliximab biosimilar (CT-P13) with referenced Infliximab in terms of efficacy,safety and quality
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2016
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2016 New trial record